Strata Critical Medical (SRTA) investor relations material

Company background and strategic evolution

• Transitioned from B2C passenger helicopter transport to a focused organ transplant logistics provider, going public via SPAC in 2021 and rebranding after divesting the passenger business.

• Achieved significant organic revenue growth in transplant logistics, scaling from $20 million to $170 million by 2025.

• Now operates one of the largest U.S. healthcare logistics networks, with over 400 clinicians and a national footprint.

Business model and operations

• 85% of revenue is transplant-related, with 70% from air logistics using a fleet of 35 aircraft and 55 ground vehicles across 20 bases.

• Offers integrated, modular services including logistics, organ placement, perfusion, and surgical recovery, allowing customers flexibility.

• Maintains high clinical standards through clinician-led operations, robust training, and regulatory oversight.

Industry growth drivers and market positioning

• Structural growth driven by supply-demand imbalance in organ transplants, with over 100,000 on waiting lists and only 50,000 transplants annually.

• Adoption of perfusion technology and regulatory changes have accelerated industry growth from low to mid/high single digits.

• Company has outpaced industry growth with 15% organic CAGR in logistics, aided by new customer acquisition and longer organ travel distances.